The FDA approved Tyrvaya nasal spray for the treatment of signs and symptoms of dry eye disease, according to a press release from Oyster Point Pharma.
Tyrvaya (varenicline solution 0.03 mg), formerly called OC-01, is the first approved nasal spray for the treatment of dry eye disease.
“The approval of Tyrvaya nasal spray marks a milestone for patients and eye care professionals by providing a new drug treatment option for the signs and symptoms of dry eye disease with a differentiated route of administration that is believed to leverage a nerve pathway that can be accessed within the nose,”